Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 13/20 | 0.58 |
| ▸ | NPC1 | O15118 | 13/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.58 |
| ▸ | TP53 | P04637 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | PKM | P14618 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709542 | 0.85 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL6707874 | 0.83 | NPC1 (0.62) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL6707187 | 0.81 | NPC1 (0.61) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL6709452 | 0.78 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL6707274 | 0.74 | HPGD (0.65) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL6712467 | 0.74 | NR3C1 (0.51) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL5460655 | 0.74 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL15867670 | 0.73 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL6710654 | 0.72 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL27179668 | 0.72 | RAB9A (0.90) | RAB9ANPC1SMN1; SMN2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102489-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | SUGEN, INC. | 2004-05-27 | — | — | US | disclosed |
| US-6649635-B2 | For therapy of cancer | SUGEN, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20020065283-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | MCMAHON GERALD (US) | 2002-05-30 | — | — | US | disclosed |
| EP-1012150-A4 | HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS | SUGEN INC (US) | 2002-05-29 | — | — | EP | disclosed |
| US-6316479-B1 | ANTICANCER AGENTS | SUGEN, INC. | 2001-11-13 | — | — | US | disclosed |
| EP-1012150-A1 | HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS | Sugen, Inc. (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998052944-A1 | HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS | SUGEN, INC. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065283-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | ABL1, ERBB2, PRKDC | RAB9A 1132/4885NPC1 2134/4885SMN1; SMN2 2016/4885 |
| US-20040102489-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | ABL1, ERBB2, PRKDC | RAB9A 1132/4885NPC1 2134/4885SMN1; SMN2 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.